Project Grant HT94252410348
Award Date
8/1/24
Completion Date
7/31/26
Dollars Obligated
$264K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
The Defense Health Agency awarded a $970,871 Project Grant to Brigham & Women's Hospital Inc. for the project "TARGETING METASTATIC LUNG TUMORS WITH GENE-EDITED AND ENGINEERED STEM CELLS". The grant, funded through the Military Medical Research and Development program (CFDA 12.420), aims to develop innovative treatments for lung cancer and other conditions relevant to military personnel and civilians. Brigham & Women's Hospital, a non-profit healthcare and research institution,...
This federal Project Grant award, valued at $772,626.00, was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports preclinical validation of gene therapy in mouse models of tuberous sclerosis complex (TSC) and lymphangioleiomyomatosis (LAM) at Brigham & Women's Hospital, a prominent academic medical center and research institution in Boston, Massachusetts. The research aims to develop innovative gene therapy...
This $437,906 project grant awarded on September 30, 2023 by the Defense Health Agency supports research by Brigham & Women's Hospital Inc. to develop enhanced immunotherapy and targeted therapy approaches for non-small cell lung cancer. The project is funded through the Department of Defense's Military Medical Research and Development program (CFDA 12.420), which supports a wide range of biomedical research efforts targeting improved healthcare for Service Members, Veterans, and the public....
This Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $566,810.00 to Brigham & Women's Hospital Inc., a non-profit hospital and research institution in Boston, MA, to support research on the neural regulation of small cell lung cancer progression. The award period is from September 1, 2023 to August 31, 2025. Brigham & Women's Hospital Inc. has previously conducted biomedical research and provided...
The Defense Health Agency awarded a $682,266 Project Grant to Brigham & Women's Hospital Inc. under the Military Medical Research and Development program (CFDA 12.420) on May 15, 2024. The grant supports research to develop targeted endothelial cell-derived extracellular vesicle nanoparticles for immunotherapy against brain cancer, with a performance period ending on May 14, 2026. As a subsidiary of Partners Healthcare System Incorporated, Brigham & Women's Hospital has extensive...
Brigham & Women's Hospital Inc. was awarded an $895,001 project grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program. The two-year award will support in vitro studies targeting proinflammatory mediators to restore regulatory T cell homeostatic expansion and function in amyotrophic lateral sclerosis. The research aims to develop surrogates for in vivo applications in investigating medical solutions for the...
The Defense Health Agency awarded a $1,318,799.00 Project Grant to Brigham & Women's Hospital Inc. in Boston, MA on June 15, 2023 under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "THE BRIDGE PROJECT: BROADENING THE REACH OF IMAGING, DIAGNOSTICS, AND GENETIC EVALUATION", will fund research and development to transform healthcare for U.S. military service members and the public through innovative medical solutions for the battlefield and...
The Department of the Army Medical Command awarded Brigham & Women's Hospital Inc. a $749,999 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to investigate lymphocyte dynamics and identify early biomarkers for systemic lupus erythematosus (SLE). The three-year award, beginning September 30, 2022, will support research to dissect lymphocyte dynamics and behavior through single-cell profiling and other advanced techniques to uncover pathways and...
This $1,428,720.00 Project Grant was awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program to Brigham & Women's Hospital Inc. in Boston, Massachusetts. The grant supports a 4-year research project, from August 1, 2025 to July 31, 2029, to investigate the degradation of the menin/KMT2A protein complex for the treatment of myeloid neoplasms. This research aims to develop innovative therapeutic approaches for these...
This federal Project Grant award of $855,709.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by Brigham & Women's Hospital Inc. to target mitochondrial metabolism in Tuberous Sclerosis Complex. The 3-year project, running from September 1, 2023 to August 31, 2026, aims to transform healthcare for Service Members and the American public through innovative and impactful biomedical research on this rare...